AmpliTech Group Inc. (NASDAQ: AMPG)

The QualityStocks Daily Newsletter would like to spotlight AmpliTech Group Inc. (AMPG).

AmpliTech Group (NASDAQ: AMPG), a designer, developer and manufacturer of state-of-the-art signal-processing components and semiconductor chips for satellite and 5G communications networks, defense, space, and other commercial applications, today announced plans to open a MMIC chip design center in Texas. According to the update, AmpliTech expects the facility, with a team of highly experienced MMIC design professionals, to be fully operational by year-end 2021. “The formation of the MMIC Design Center illustrates AmpliTech’s continued focus on innovation and technology leadership, as well as our risk and cost-management disciplines,” said Fawad Maqbool, CEO of AmpliTech. “We are building our company to meet the substantial demand we see for best-of-breed, low-noise amplifiers and other technologies across satellite communications, 5G/telecommunications, defense, aerospace, and other markets. Furthermore, we are confident that the capabilities, cost, form factor, flexibility, and scalability of MMIC-based products will be very well received across our end markets.” To view the full press release, visit https://ibn.fm/HFbim

AmpliTech Group Inc. (NASDAQ: AMPG) (NASDAQ: AMPGW) designs, develops and manufactures custom radio frequency (RF) components for the commercial, SATCOM, space and military markets. In addition to developing new products for the 5G/6G wireless ecosystem and infrastructure, the company has placed focus on the development of leading-edge solutions in quantum computing in support of U.S. efforts to reach the coveted position of quantum supremacy. The company maintains a commitment to R&D that allows it to remain at the forefront of emerging technologies. AmpliTech aims to use its advanced techniques and IP to provide tomorrow’s technology today, improving everyone’s quality of life.

AmpliTech was founded by Fawad Maqbool in 2002 to fill the need for affordable, high-quality, customized and state-of-the-art amplifiers and components. Headquartered in Bohemia, New York, the company currently has distributors and representatives available worldwide.

Product Portfolio

AmpliTech’s mission is to develop quality, state-of-the-art microwave amplifiers by leveraging its experience, proven technical expertise and superior design heritage. The company’s products cover a frequency range from 50 kHz to 44 GHz, with plans to eventually offer designs up to 100 GHz. Its current catalog includes:

Amplifiers

• Low Noise Amplifiers
• Cryogenic Amplifiers
• Limiting Amplifiers
• Waveguide Amplifiers
• Medium/High Power Amplifiers
• Surface Mount Amplifiers

Passive Components

• End Launch Rectangular Adapters
• Rectangular Adapter to COAX
• Power Dividers

All the company’s products come with a satisfaction guarantee, as the company is fully committed to providing only high-quality products free from manufacturing and material defects and guaranteed to perform according to applicable specifications.

Consulting Services

Leveraging more than 100 years of combined experience in microwave systems and component design ranging from active components to passive devices, AmpliTech also provides valuable consulting services and technical assistance to its customers.

With capabilities ranging from initial design to final manufacturing and delivery, the company’s team also offers project management services and advice on both technical aspects and how to handle business issues such as resource allocation, customer contact, budget restraints, time limits and more.

Other key benefits of AmpliTech consulting services that can give its customers a definitive edge include:

• Timely technical assistance
• Little or no learning curve
• Less long-term costs associated with full-time employees with benefits and salaries
• Availability when necessary
• Customer support with schedules, project management and on the job training
• Access to technology
• Partnering for manufacturing and/or complete turn-key product solution
• Personal guidance from concept to development
• Custom designs for each application

Market Outlook

The global microwave devices market was valued at $7.44 billion in 2019 and is expected to grow at a CAGR of 3.23% and reach $9 billion by 2025 (https://nnw.fm/zqMEk). Governmental expenditures in the defense and space communications sectors are expected to expand the opportunities for growth within the industry.

AmpliTech continues to follow its strategy of identifying key elements in today’s technological revolution. It is leveraging its technical expertise and experience to align product portfolios and IP with innovation (https://nnw.fm/rVzxX). The company has plans to be a catalyst in the enhancement, development and distribution of breakthroughs in the following sizeable markets:

• High Speed Terrestrial and Satellite Terminals (SATCOM, “Internet in the Sky”)
• 5G/Wi-Fi6E and 6G wireless infrastructure (Cellular Base Stations, Small Cells, Private Wi-Fi Networks)
• IoT (Internet of Things)
• Cloud Farms, Big Data and MEC architecture
• Quantum Supercomputers/Quantum Research
• Deep Space Astronomy
• Autonomous Self-Driving Vehicles
• Telemedicine, AR/VR (Augmented and Virtual Reality)
• Drones, UAVs (Unmanned Aerial Vehicles)
• Cyber-security
• Military/Defense ECM/EW

Management Team

Fawad Maqbool is the Founder, President, CEO and CTO of AmpliTech Group Inc. He has been in the microwave industry for over 30 years. Mr. Maqbool spent 14 years developing state-of-the-art amplifiers and components for MITEQ Inc., a leading microwave and communications equipment supplier. He founded AmpliComm in 2000, which was subsequently acquired by Aeroflex Inc. Mr. Maqbool has management and design experience, which has led to the development of microwave technology on a commercial and military level. He holds a B.S.E.E in Microwave Engineering and a B.S.E.E in Bio-Medical Engineering from CUNY and an M.S.E.E from the Polytechnic University of New York.

Louisa Sanfratello is the company’s CFO. She is a Certified Public Accountant (CPA) and has worked in various industries since 1998. During this time, she held roles as an accountant for charities and schools, consisting of the preparation of official financial documents and day-to-day financial management requirements. Ms. Sanfratello began her professional career in 1987 at Holtz, Rubinstein & Co., a public accounting firm. She gathered two years of experience there before gaining her CPA and taking on more challenging roles.

Brandon Worster is the company’s Director of Engineering. He joined AmpliTech at the end of 2019, bringing over 14 years of design and management experience. His specialty is Low Noise and Medium Power Amplifiers, but Mr. Worster also has vast experience with various systems, including RF/Microwave devices and systems. He holds a master’s degree in electrical engineering and is an adjunct professor at Farmingdale University in New York.

John P. Pastore is AmpliTech’s Director of Sales. He has worked in the microwave industry for more than 35 years, including time with some of the industry’s leading names. Mr. Pastore is a hands-on professional who has experience that spans over 20 years with progressive roles that blend technical, manufacturing, customer service and management expertise. He is an extremely valuable asset to the company as it moves forward due to his business savvy approach and deep industry knowledge. He has a B.S. in Business Management.

M. Syed handles Technical Sales and is the company’s Director of IT. He is an electrical engineer with more than 10 years of business experience. Since 2011, he has led Technical Sales for AmpliTech, and he recently became the President and CEO of his own company while also serving as Chief Technical Sales consultant for numerous other companies and groups in New York City. Mr. Syed has been in the IT industry for 25 years. He is a Computer Engineer by trade and a Certified Netware Engineer and Microsoft Certified Systems Engineer.

AmpliTech Group Inc. (AMPG), closed Monday's trading session at $3.6, up 0.278552%, on 2,863,747 volume with 9,128 trades. The average volume for the last 3 months is 2.864M and the stock's 52-week low/high is $0.906/$19.80.

Recent News

• AmpliTech Group Inc. (NASDAQ: AMPG) - InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Announces Launch of Texas-Based MMIC Semiconductor Chip Design Center
• InvestorNewsBreaks - AmpliTech Group Inc. (NASDAQ: AMPG) Making Strategic Investments to Tap into Hyper-Growth Opportunities
• AmpliTech Group Inc. (NASDAQ: AMPG) Expanding Through Focus on Quality, Performance, Hyper-Growth Opportunities

Kaival Brands Innovations Group Inc. (KAVL)

The QualityStocks Daily Newsletter would like to spotlight Kaival Brands Innovations Group Inc. (KAVL).

Kaival Brands (NASDAQ: KAVL), the exclusive global distributor of products manufactured by Bidi Vapor LLC, has closed its previously announced underwritten public offering of 4,700,000 shares of its common stock and accompanying warrants to purchase up to 3,525,000 shares of common stock. According to the update, Kaival Brands secured approximately $8.0 million in gross proceeds with each share of common stock sold together with 0.75 warrants at a combined public offering price of $1.70. The warrants are exercisable immediately at a price of $1.90 per share and will expire five years following the date of issuance. Kaival Brands has additionally granted the underwriters a 45-day option to purchase up to an additional 705,000 shares of common stock and/or warrants to purchase 528,750 shares of common stock to cover over-allotments at the public offering price, less the underwriting discount, of which Maxim Group LLC has exercised its option to purchase an additional 528,750 warrants. The company offered all of the shares of common stock and warrants, and Maxim Group LLC acted as sole book-running manager for the offering. To view the full press release, visit https://ibn.fm/G7GG5

Kaival Brands Innovations Group Inc. (KAVL) is focused on growing and incubating innovative and profitable products into mature, dominant brands. It aims to develop internally, acquire or exclusively distribute these products, helping them grow into market-share leaders by providing superior quality that is recognizable in their individual industries.

Formerly known as Quick Start Holdings Inc., the company changed its name to Kaival Brands Innovations Group Inc. (also known as Kaival Brands) in July 2019. Headquartered in Grant, Florida, the company commenced business operations on March 9, 2020.

Bidi™ Stick – Revolutionizing the Vaping Experience

On March 9, 2020, Kaival Brands entered into a partnership with Bidi Vapor LLC. The latter granted Kaival Brands exclusive global distribution rights for the innovative Bidi™ Stick.

Bidi™ Stick is a completely self-contained disposable product that is tamper-proof and recyclable. The innovative product is made from high-quality components and equipped with a long-lasting battery and class A nicotine. Its product engineering also includes a sensitivity control system, along with a proven mechanism designed to help identify and eliminate counterfeit products.

Available in 11 flavors, the Bidi™ Stick offers a premium vaping experience for adult consumers only. From its packaging design to its marketing strategies, Bidi Vapor makes sure that everything is compliant with government regulations.

On March 31, 2020, Kaival Brands partnered with QuikfillRx Digital as a digital service provider to help promote and commercialize the Bidi™ Stick. As a direct result of the partnership, Kaival Brands received back-to-back orders for the vaping device, totaling approximately $135,000, from sizable national convenience chains.

On September 8, 2020, the company announced that Bidi Vapor had submitted its Premarket Tobacco Product application (PMTA) to the U.S. Food and Drug Administration (FDA) for review. In total, over 285,000 pages of research, studies and surveys were submitted to support the application of Bidi™ Stick’s 11 variants.

“We are confident that, upon review, the FDA will authorize Bidi Vapor’s Bidi™ Stick for continued marketing in the United States,” Niraj Patel, President and CEO of Kaival Brands, stated in a news release (http://nnw.fm/unAyG).

Bidi Vapor is an industry leader in recycling – a position that was furthered through the creation of the Bidi Cares Initiative. The program encourages users to recycle their used Bidi™ Sticks instead of trashing them. As motivation, Bidi Vapor offers a free Bidi™ Stick for every 10 used devices recycled by a consumer. Kaival Brands is the exclusive recycling provider for the initiative.

Partnership Impact and Market Outlook

Bidi Vapor is a related party to Kaival Brands, as it is owned by Kaival Brands CEO Nirajkumar Patel. Patel is also the majority stockholder of Kaival Brands, placing both entities under common control.

The partnership has already had a positive impact on Kaival Brands, helping the company expedite growth, as evidenced by its Q2 financial results. According to Kaival Brands’ consolidated fiscal results for the quarter that ended on April 30, 2020, its revenues grew to approximately $22.5 million from no revenue in the same quarter of 2019. The company also scored a gross profit of $4.2 million for the three-month period. Net income was reported at $2.8 million for the quarter, compared to a net loss of about $4,000 in the second quarter of 2019. The company ended the second quarter of 2020 with a cash balance of $2 million (http://nnw.fm/44sq4).

The positive results are primarily an effect of Bidi™ Stick distribution amid the growing worldwide demand for high-quality vape products, as Patel explained in a news release. “Our focus now is to continue to increase revenues by increasing Bidi Vapor’s market share in the vaping industry,” he added.

Internationally, Kaival Brands has already taken steps to expand distribution of the Bidi™ Stick into Guam, Canada, the European Union, the United Kingdom, Australia and New Zealand.

To this end, the company has set up a market engagement and sales force to reach a higher volume of retail and wholesale customers. It also created a dedicated customer support team to provide high-quality service and an enhanced customer experience.

Kaival Brands is dedicated to developing innovative and viable options for adults who use tobacco and vape products and want a premium experience. The company wants to set higher standards to transform perceptions and elevate consumer experience in the vape and CBD industries, with a goal of increasing market share in the ever-growing vaping industry. In 2019, the reported global market for the vaping industry alone was $12.4 billion. These forecasts indicate a potential CAGR of 23.8% through 2027.

Cancellation of 300 Million Shares of Common Stock

In August 2020, the company canceled 300 million shares of common stock, marking a 52.1 percent reduction in its issued and outstanding shares of common stock (http://nnw.fm/W7s9T). Currently, the company’s outstanding common shares total 277,282,630. The cancelation was done in exchange for three million shares of Series A Preferred Stock. The Series A Preferred Stock cannot be converted before November 2023, barring any event that may trigger early conversion.

According to Patel, this move will benefit all shareholders and help maintain stability of the market pricing of remaining common stock. The overall goal is to increase value for long-term investors.

Management Team

Nirajkumar Patel is the CEO, CFO, President, Treasurer and Director of Kaival Brands and owner of Bidi Vapor LLC. In 2004, Patel received a Bachelor of Science in pharmaceutical sciences from AISSMS College of Pharmacy in Prune, India. He moved to the United States in 2005, and he continued his education at the Florida Institute of Technology, where he graduated in 2009 with a master’s degree in medicinal and pharmaceutical chemistry. He currently holds a Six Sigma Black Belt Certification.

Eric Mosser is the COO, Secretary and Director of Kaival Brands. Mosser attended Arizona State University, where he studied business management. In 2004, he graduated from Rio Salado College with an associate degree in applied science in computer technology.

Kaival Brands Innovations Group Inc. (KAVL), closed Monday's trading session at $1.34, up 2.2901%, on 481,713 volume with 1,479 trades. The average volume for the last 3 months is 471,402 and the stock's 52-week low/high is $1.21/$43.80.

Recent News

• Kaival Brands Innovations Group Inc. (KAVL) - InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Secures $8M in Underwritten Public Offering
• InvestorNewsBreaks - Kaival Brands Innovations Group Inc. (NASDAQ: KAVL) Releases Pricing of Proposed Public Offering
• Kaival Brands Announces Pricing of $8.0 Million Underwritten Public Offering of Common Stock and Warrants

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF)

The QualityStocks Daily Newsletter would like to spotlight Avricore Health Inc. (OTCQB: AVCRF).

• Through HealthTab, its flagship offering, Avricore is enabling consumers to access important health information in a convenient way and at a time that is fitting for them
• HealthTab is a turnkey point-of-care testing solution that combines a secure, cloud-based platform with point-of-care technologies
• In a rapidly evolving world of healthcare that has seen consumers become more health-conscious and prompted the adoption of digital technologies, Avricore is playing a critical role
• Avricore has appointed Oak Hill Financial Services Inc. to provide the company with investor relations and advisory services.

When reflecting upon the impact of the COVID-19 pandemic, it is hard to miss the fact that it has accelerated change across the global health care ecosystem. It has made consumers more health-conscious, with many taking more initiative, as evidenced by their willingness to utilize technologies to get information on health issues, as well as track their health and use the data generated to make health-related decisions. They are also accessing and utilizing their medical record data. In this rapidly evolving world of health care, Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF), a health diagnostics technology innovator, is taking part in the digital transformation as well as satisfying emerging consumer preferences through its flagship offering, HealthTab(TM). 

Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering, HealthTab™ (a wholly owned subsidiary), the company aims to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab

HealthTab is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centers’, or CDCs) and connects them on a single, cloud-based platform.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery and empowers patients to take more control of their health. It also reduces costs and waiting times while providing many potential revenue streams, including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets and third-party app integration through API.

Agreement with Shoppers Drug Mart

In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab platform. This agreement gives patients access to point-of-care blood screening and health-data management for potential risks relating to diabetes and cardiovascular conditions using HealthTab-integrated Afinion 2™ analyzers provided by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE: ABT), the global health care company and diagnostics leader in Canada. In May 2021, the company signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2 and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near Term Goals

Near term goals for Avricore include expansion into more pharmacies across Canada, followed soon after by entering the U.S. and UK markets. The company has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like those with Abbott and select Shoppers Drug Mart pharmacies advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacies.

Market Outlook

In 2020, the global point-of-care testing (POCT) market was valued at $34.49 billion and expected to expand at a compound annual growth rate (CAGR) of 9.4 percent to reach a projected $81.37 billion by 2028. This upsurge is expected to be driven largely by increased demand for screening and management tools for chronic diseases, as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Management Team

Avricore’s leadership team brings a diverse portfolio of expertise across the health care and biotech industries, as well as technology, finance and communications. Together, they share a common vision of moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner is the CEO of Avricore. He has over 15 years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He owned and operated TOUCH Marketing, a boutique marketing and communications firm based in Vancouver, from 2007 to 2013. Mr. Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall is the Chairman and a Director of Avricore. His leadership spans five different companies. He is currently the Chairman of RepliCel Life Sciences and a member of the boards of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute. Mr. Hall also served as Chairman of Perceptronix Medical Inc.; Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals Inc.; President & Director at Newcastle Resources Ltd.; and Chairman for LifeSciences British Columbia.

Kiki Smith is Avricore’s CFO. She has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors. Ms. Smith is a member of the Chartered Professional Accountants of British Columbia and has a bachelor’s degree in economics from the University of British Columbia.

Rodger Seccombe is the Head of Avricore’s HealthTab division and the co-founder and former CEO of HealthTab Inc. Mr. Seccombe has over 20 years of experience launching and running companies in software, health care technology and clean energy. He is a recognized industry expert in direct-to-consumer and point-of-care testing technology. In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health Inc. (OTCQB: AVCRF), closed Monday's trading session at $0.119, even for the day. The average volume for the last 3 months is 500 and the stock's 52-week low/high is $0.06/$0.48562.

Recent News

• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Taking Part in Health Care Digital Transformation Through HealthTab(TM) Platform
• InvestorNewsBreaks - Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) Simplifying Patients' Lives with Easy Access to Point-of-Care Testing
• Avricore Health Inc. (TSX.V: AVCR) (OTCQB: AVCRF) and the Critical Need for Better Disease Diagnosis

reAlpha

The QualityStocks Daily Newsletter would like to spotlight reAlpha

• American Cannabis Partners has focused on the safety of shareholders’ investments from day one
• CEO brought the culture and story of the Jamaican people to influence the US cannabis industry
• ACP seeks to improve the lives of individuals through cannabis and business in all that it does

When it comes to building steady growth and reducing risk, Stephen Jordan, CEO of American Cannabis Partners (“ACP”) focuses on “assets, assets, assets — and then build the operations out.” This is a rarity within the cannabis industry where most companies create a product first and if something happens where they are unable to make that product, they go under.

reAlpha is the Robinhood of Airbnb investments, representing the intersection of modern technology and lasting assets. A new wave of investment opportunities in real estate has emerged, and Airbnb short-term rentals are changing hospitality and travel on a global scale. Previously, only accredited investors have had access to the best real estate deals, but reAlpha is democratizing this lucrative new model, empowering anyone to generate wealth as a reAlpha member. reAlpha uses its proprietary, disruptive technologies to level the playing field, unraveling the industry’s high barriers to entry and bringing the power of real estate investing to the “99 percent.”

The company’s unique model allows investors to benefit from both the superior returns of short-term rental income and increases in property value through renovation and appreciating markets. reAlpha likens this double investment return to seeing two desserts on a dinner menu and ordering both.

The company seeks to open up access to real estate investing by letting regular people buy fractional ownership of short-term rentals using reAlpha’s smartphone app. The reAlpha app simplifies the real estate investing process. In the app, investors can check out the company’s most current properties offered for investment. If they choose to invest, they become members of a syndicate invested in a specific short-term rental property. Syndicate members receive quarterly dividend payments from rental revenue generated by the property in which they invested. The reAlpha model merges the most historically stable asset – real estate – with technology and the sharing-economy business model of the future – Airbnb.

The company handles all property management functions and believes short-term rentals are no longer purely transactional and occupancy-driven. reAlpha reimagines the entire guest experience end-to-end to make sure the reAlphaHouse is the ultimate on-demand rental property. The company plans to implement various technologies, including smart locks, voice-activated electronics, home automation systems, and innovative furnishings, to create an unparalleled guest experience. When guests have exceptional stays, investors enjoy maximized profits.

How it Works

reAlpha has identified specific markets in which to purchase short-term rentals across the globe. The company prefers to buy 100 to 500 properties in each market. reAlpha uses artificial intelligence technology, dubbed reAlphaBRAIN, to select “unicorn properties,” the best available opportunities in the market for investment. The AI software can quickly evaluate thousands of property listings based on 25+ factors and assign each a reAlphaScore, projecting how Airbnb Viable the property is, as well as its projected value in the housing market.

For a minimum investment of $2,500, an investor can purchase equity in a specific reAlpha property, similar to how they would buy stock or shares in a company. reAlpha matches the investor with other like-minded backers to form a syndicate, so together they can cover a down payment on the selected property. Investment properties usually require a down payment of 25 percent of the purchase price, but, with reAlpha properties, the down payment is only 10 percent because of the company’s relationships with lenders, making the initial investment more affordable.

reAlpha maintains a majority stake in each investment syndicate, retaining 51 percent ownership in each purchased property and ensuring their interests are always aligned with investing members. Properties are typically refinanced after 12 to 16 months, freeing equity for reinvestment in additional properties. The company uses its AI software to predict optimum timing to sell properties in order to extract maximum value for investors. Gains are reinvested in additional properties. However, reAlpha also believes that real estate investing is more than financial returns. It includes the pride of ownership and the freedom of financial security. reAlpha members have access to their property when it is not rented out on Airbnb. The company is driven every day to create not only lucrative returns for its members but also to deliver exceptional experiences and positive impact in the communities in which reAlpha lives and operates.

Market Outlook

There are an estimated 7.4 million short-term rental properties worldwide. The total asset value of this global market is projected at $1.2 trillion. In the U.S. there are about 1.8 million short-term rental properties. These have an estimated asset value of $933 billion. Brain Chesky, the CEO of Airbnb, recently stated that there is a shortage of properties to meet demand and that the company will need “millions of more hosts.” reAlpha is projecting that the company and its investors will own 5,000 short-term rental investment properties by 2025. reAlpha forecasts annual revenue of $434 million by 2025.

Management Team

Giri Devanur is the CEO and co-founder of reAlpha. Prior to founding reAlpha, he served as president and CEO of enterprise software company Ameri100 Inc. from its founding in 2013. He scaled Ameri100 from zero to $50 million in revenue and took the company public in 2017. That same year, he was named E&Y Entrepreneur of the Year. He immigrated to the U.S. with virtually no possessions and $65 in the bank. He earned a Master’s in Technology Management from Columbia University, where he continues to mentor aspiring entrepreneurs.

Monaz Karkaria is the COO and co-founder of reAlpha. Prior to reAlpha, she founded real estate management firm Ben Zen Properties LLC. She has also worked in branch operations for Citibank. Before her involvement in Citibank, she worked at Berlitz in Sao Paulo, Brazil, as an ESL business coach and consultant for various international business clients like GE, Google, PepsiCo and others. She began her career in sales and marketing at Smith & Nephew Dubai. She is also a popular real estate coach and speaker.

Mike Logozzo is the CFO of reAlpha. Prior to joining the company, he served as Managing Director, Americas for innovation advisory firm L Marks. Before that, he was General Manager, Financial Services Operations, Americas Region for BMW Group Financial Services, where he also held Special Projects Manager and CIC Strategy Manager positions.

Christie Currie is the CMO of reAlpha. Previously, Christie launched her own business in the MedTech space, Zandaland, where she worked closely with large enterprises and health care systems. Currie’s work in the startup community led her to London-based corporate innovation firm L Marks, where she led world-leading corporations in retail, supply chain and logistics, and health care to identify strategic areas of need and successfully engage industry-disrupting startups. Currie has mentored hundreds of these startups, helping them to align their technology solutions with market needs.

Recent News

• reAlpha - reAlpha Launches Public Offering under Regulation A+
• InvestorNewsBreaks – reAlpha to Showcase Story and Participate in Equity Crowdfunding Week 2021
• reAlpha Looks to Democratize Investment Access to Short-Term Rental Market Amidst Record Consumer Demand

Net Element (NASDAQ: NETE)

The QualityStocks Daily Newsletter would like to spotlight Net Element (NETE).

As Americans grow increasingly fond of sports utility vehicles (“SUVs”) and pickup trucks, the demand for sedans has declined significantly. Consequently, automakers have begun eliminating sedans from their lineups, with automakers such as Ford, Chrysler and Lincoln abandoning sedans years ago. As it stands, the Toyota Avalon, Volkswagen Passat and the Mazda 6 will be the next victims. But while the popularity of larger vehicles has pushed sedans into the background, some experts say it is the mass adoption of electric vehicles (“EVs”) that will finally push them out of the market. If the switch to electric forms of vehicular transportation carries the price of bringing an end to the era of sedans, no one will fault sector players such as Net Element (NASDAQ: NETE) since the bigger goal is to reduce the rate at which global warming is taking place.

On June 15, 2020, Net Element announced its entry into a binding letter of intent to merge with privately-held Mullen Technologies Inc., a Southern California-based electric vehicle company, in a stock-for-stock reverse merger in which Mullen’s stockholders will receive the majority of the outstanding stock in the post-merger company. The proposed merger is currently pending the execution of a definitive agreement, shareholder vote and regulatory approval.

Net Element Inc. (NASDAQ: NETE) is a global financial technology and value-added solutions group that supports electronic payments acceptance in an omni-channel environment spanning across point-of-sale, e-commerce and mobile devices. The company operates a payments-as-a-service transactional model and value-added services platform for small to medium enterprises in the U.S. and selected emerging markets.

Net Element believes the future of global commerce is being revolutionized as consumers quickly migrate toward omni-channel shopping utilizing mobile devices, desktop, and online services. The company’s all-in-one payment solutions support and unify a whole range of applications through a single, robust platform, allowing global onboarding and support for multiple payment methods.

Net Element has also launched a blockchain-focused business unit that will develop and deploy blockchain technology-based solutions. Net Element expects the new division to create a decentralized crypto-based ecosystem that will act as a framework for an unlimited number of value-added services, connecting merchants and consumers in a seamless, economically efficient transaction. This new business unit intends to also identify and invest in unique projects that decentralize and disrupt the payment processing industry by combining blockchain technology and real-world applications with talented development teams, strong fundamentals and addressable markets large in size.

“We believe that we’re at the dawn of a new evolution where additional digital payment methods are being introduced,” Net Element chairman and CEO Oleg Firer, says. “Introduction of our division focused on blockchain as part of the NASDAQ-listed entity will add transparency and compliance assurance to our investors as well as provide access to deploy value-added services to over 20 million electronic commerce clients that are currently part of Net Element’s growing network.”

Net Element clients are treated to customized solutions that provide the flexibility needed to keep up with customers. Among the services offered are mobile payment apps that accept payments anywhere, anytime; cloud-based solutions built to increase productivity and enhance revenue for clients and partners; marketing solutions that turn lookers into buyers; and business analytics that make it easy for clients to monitor business metrics, engage with customers and compare the competition. Its multi-channel platform combines e-commerce, offline, point-of-sale, comprehensive back office tools, mobile point-of-sale, credit scoring and customer interaction in one powerful platform-as-a-service technology.

Net Element owns and operates a global mobile payments and transactional processing provider, TOT Group, Inc., with the following subsidiaries:

• Unified Payments – An award-winning, customized mobile billing and payments solution, recognized by Inc. Magazine as the No. 1 Fastest Growing Company in America in 2012.
• Aptito – A next-generation, all-in-one, cloud-based restaurant management and point-of-sale payments platform using wireless technology.
• Payonline – A fully integrated, processor agnostic electronic commerce platform.

Net Element is ranked on Deloitte’s Technology Fast 500™ list of North America’s 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in both 2017 and 2018, during which the company grew 190 percent and 183 percent, respectively. The company credits its progression to organic growth in its North America Transactions Segment, specifically the success of its Unified Payments brand, which focuses on value-added payment acceptance solutions for small to medium enterprises in the United States.

Net Element was also listed among South Florida Business Journal’s 2016 fastest growing technology companies.

Leveraging its suite of application performing interfaces (APIs) and connectors, Net Element powers commerce for businesses of all sizes through multi-channel platforms, all-in-one digital solutions, and end-to-end encryption of cardholder data utilizing tamper resistant hardware that ensures integrity and simplifies security.

Leading this innovation is chairman and CEO Oleg Firer, who is responsible for the overall vision, strategy and execution of the company’s mission of powering global commerce. He is joined by CFO Jeffrey Ginsburg, CPA, and Steven Wolberg, the company’s chief legal officer and secretary. Each corporate officer brings a unique blend of leadership, vision, experience and creative energy to the company.

From mobile payments and value-added transactional innovations like Aptito to e-commerce and retail payment transaction processing brands like Payonline and Unified Payments, Net Element is transforming the online and mobile experience.

Net Element (NETE), closed Monday's trading session at $7.69, off by 6.4477%, on 159,885 volume with 1,150 trades. The average volume for the last 3 months is 159,885 and the stock's 52-week low/high is $5.68/$19.15.

Recent News

• Net Element (NASDAQ: NETE) - Experts Say Switching to EVs Could Signal End of Sedans
• EV Sales Accelerate in 2021
• InvestorNewsBreaks - Net Element Inc. (NASDAQ: NETE), Mullen Automotive Inc. Release Update Letter to Shareholders

Save Foods Inc. (NASDAQ: SVFD)

The QualityStocks Daily Newsletter would like to spotlight Save Foods Inc. (NASDAQ: SVFD).

Save Foods (NASDAQ: SVFD), an Israeli-based agrifood tech company focused on developing and selling eco-friendly products specifically designed to extend the shelf life and ensure the safety of fresh fruits and vegetables, has started a large commercial treatment program. SVFD is working on the project with Galilee Export, a leading Israeli avocado packer and the second-largest exporter of fresh produce in Israel. According to the announcement, Galilee accounts for an estimated 50% of Israel’s total avocado exports; the company also exports citrus, mangoes, Medjoul dates, pomegranates, grapes, sweet peppers, carrots, lychees, peaches, nectarines and more. To view the full press release, visit https://ibn.fm/AaZMn

Save Foods Inc. (NASDAQ: SVFD) is an agri-food tech company focused on developing and selling eco-friendly products specifically designed to ensure food safety and extend the shelf life of fresh fruits and vegetables. The company is focused on addressing two of the most significant challenges faced by the industry: (1) food waste and loss, and (2) food safety.

Fungi like mold and yeast, as well as foodborne pathogens, are typically responsible for fresh produce spoilage and foodborne illness. Save Foods’ integrated solutions improve safety, freshness and quality every step of the way, from field to fork. The company’s natural products control human and plant pathogens, allowing growers, packers and food retailers to reduce waste and boost revenues. More food ends up on consumers’ plates, and less ends up in landfills.

Save Foods’ products use all-natural ingredients to protect fresh produce from microbial spoilage and pathogens with zero toxicity. The company’s treatments leave no harmful residues on produce or in the environment and maintain product freshness over time. Fresh produce treated with Save Foods’ products can already be found in supermarket chains across the U.S. and Europe. Those chains have reported that the company’s products are reducing fruit spoilage by 50% on average at the retail level. With no need for additional steps in the treatment process nor special equipment, Save Foods’ products are easy to implement and come in versatile applications suitable for the different stakeholders along the food supply chain.

Initial applications for the company’s offerings include post-harvest treatments in fruit and vegetable packing houses that process citrus, avocados, pears, bell peppers and mangos. By controlling and preventing pathogen contamination and significantly reducing the use of chemicals and their residues, Save Foods’ products not only prolong shelf life; they also ensure safe, natural and healthy food. Save Foods has the first green products that could realistically replace the different chemicals used today in food treatment while controlling waste and food safety.

Products & Technology

• SavePROTECT or PeroStar, a processing aid added to fruit and vegetable wash water and used in post-harvest treatment;
• SF3HS and SF3H, post-harvest treartment solutions to control both plant and foodborne pathogens;
• SpuDefender, for controlling post-harvest potato sprouts; and
• FreshPROTECT, for controlling spoilage microorganisms on post-harvest citrus.

Save Foods’ products are based on a proprietary blend of food acids which have a synergistic effect when combined with certain types of sanitizers and fungicides at low concentrations in a non-organic setting. The combination eliminates fungicide residues or reduces them to levels below the established Maximum Residue Levels (MRLs). The company’s fruit and vegetable wash is odorless and does not irritate human eyes, skin or airways. Save Foods’ blend does not leave any residues of toxicological concern on the treated surface of produce, and all its ingredients are classified by the U.S. Food and Drug Administration (FDA) as Generally Recognized As Safe (GRAS). There are 7 patent families related to Save Foods’ technology.

Applications

The company’s products have been commercially validated on citrus, mangos, avocados, pears, bell peppers, microgreens and various fresh cut vegetables. Save Foods is in the validation process for bananas, apples, figs, berries, lettuce, papayas and more. The company is also validating the efficacy of its products for pre-harvest treatment, starting with citrus trees.

Market Outlook

The world population is expected to grow to almost 10 billion by 2050, boosting current agricultural demand by some 50%. Providing healthy and safe food for the world’s population is one of the biggest challenges of the 21st century.

Globally, around 664 million tons of fresh fruits and vegetables are lost every year from field to fork, wasted by spoilage, and almost one in 10 people globally falls ill every year from eating contaminated food, with an estimated resulting cost around $90 billion.

Disposing of all that wasted food requires additional expense and harms the environment with resulting greenhouse gas emissions. The post-harvest food treatment market was valued at $1.5 billion in 2019 and is expected to grow to $2.3 billion by 2026, achieving a CAGR of 6.5%.

Management Team

David Palach is CEO of Save Foods. He spent over a decade with Intel Israel, where his last position was Manager of Business Development for Israel and Europe. Prior to that, he served as a controller of two of Intel’s largest factories in Israel, where he supervised a budget of over $1 billion. He also served as the CEO of B-Pure Corporation Ltd., a management and maintenance company involved in protecting and improving the environment. During his tenure, he helped turn around several struggling subsidiaries and made them profitable.

Vered Raz Avayo is the company’s CFO. Before joining SaveFoods in 2018, she spent more than 10 years as CFO at LGC, the Leviev Group of Companies. She has operated her own financial and business consultancy and has served as a director for a number of public companies in Israel.

Dan Sztybel is CEO of SaveFoods Ltd., the Israeli subsidiary of Save Foods Inc. He previously led the Life Sciences Advisory at EY Israel and early on recognized the potential of Israel as a center of innovation in the digital health space. He has been an adviser on digital health strategy to large pharmaceutical companies and is a cofounder of MyndYou, a digital health start-up focusing on cognitive impairment. He is also a co-founder of the DigitalHealth.il conference, the largest digital health conference in Israel.

Dr. Neta Matis is Vice President of R&D at Save Foods Ltd the Israeli subsidiary of Save Foods Inc . She holds a Ph.D. in organic chemistry and an MBA from Tel Aviv University. Prior to joining Save Foods in 2019, she held multiple research chemist and product development roles at Verdia Inc. and its parent company, Helsinki-based Stora Enso Oyj.

Nimrod Ben Yehuda is the founder and CTO of Save Foods Ltd. He was previously the CEO/CTO of Swissteril Water Purifications Ltd. He has also been CEO at Nir Ecology Ltd., and was Joint-CEO at NitroJet Ltd.

Dr. Art Dawson is the U.S. Business Manager for SaveFoods Inc. He has been president of The Dawson Company, which focuses on creating sales opportunities for new agricultural technologies, previously Dr. Dawson held senior industry positions like General Manager Worldwide of the Decco , the Post Harvest Division for Elf Atochem. He holds a Ph.D. in Plant Physiology from UC Riverside and is licensed in California as an agricultural Pest Control Advisor.

Save Foods Inc. (SVFD), closed Monday's trading session at $6.53, off by 3.9706%, on 15,603 volume with 156 trades. The average volume for the last 3 months is 15,603 and the stock's 52-week low/high is $1.75/$30.10.

Recent News

• Save Foods Inc. (NASDAQ: SVFD) - InvestorNewsBreaks - Save Foods Inc. (NASDAQ: SVFD) Partners with Leading Israeli Exportor to Commence Avocado Treatment Program
• InvestorNewsBreaks - Save Foods Inc.'s (NASDAQ: SVFD) Proprietary Technology Designed to Deliver Freshness and Quality, Field to Fork
• InvestorNewsBreaks - Save Foods Inc. (NASDAQ: SVFD) Completes Successful Lemon Pilot Tests in Spain with Leading Post-Harvest Service Provider

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF)

The QualityStocks Daily Newsletter would like to spotlight Red White & Bloom Brands Inc. (OTCQX: RWBYF).

• The approval by the Marijuana Regulation Agency represents RWB’s authorization to move forward with the operational strategy of its subsidiary RWB Michigan, LLC
• Michigan provides access to a market with approximately 10 million people and a consumer pool responsible for $171 million in sales – resulting in the generation of more than $23 million in tax revenue for the state’s roads, schools, counties, and municipalities
• The Sanderson property in Florida has been built to GMP specifications and is a 4,800 square foot standalone facility that is expected to help bridge the gap and satisfy the fast-growing demand in the cannabis edibles market

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), formed when privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019, is an innovator of American cannabis – adhering to the highest ethical, manufacturing, education, branding, and employment standards in the industry. The company is a superstate operator, leveraging a sizable footprint to dominate the areas in which it operates. Recently released federal data shows that the number of credit unions and banks working with cannabis businesses has increased in the last quarter. Figures show that by the end of June 2021, 706 financial institutions were actively serving marijuana clients. This is a slight increase from the 687 institutions recorded in the previous quarter. As a growing number of financial institutions become more receptive to doing business with marijuana firms, the entire sector, including companies such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF), will have one less bottleneck to deal with.

Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) is a torchbearer blazing a new frontier in American cannabis by adhering to the highest ethical, manufacturing, educational, branding and employment standards available in the industry.

Red White & Bloom is a super state operator, leveraging a sizable footprint to dominate the areas in which it operates. CEO Brad Rogers and other management members have seen the struggles of multi-state operators who have spread themselves too thin, which is why Red White & Bloom is intent on dominating each state it enters before expanding further.

Although targeting individual states in the United States, the company is headquartered in Toronto, Canada. Red White & Bloom was established after privately held MichiCann Medical Inc. merged with publicly traded Tidal Royalty in 2019.

Brands

Red White & Bloom has entered strategic brand acquisitions and partnerships aimed at helping the company expand its presence and position as one of the largest players in the United States cannabis market. Red White & Bloom is always diligently searching for brands to acquire that will provide additional value to the company and expand its national footprint.

The company’s current brand portfolio includes:

• Platinum Premium Cannabis Products (PV): Platinum uses innovative thinking, honesty and responsibility to remain at the forefront of the cannabis industry. PV holds itself and its partners to the highest standards, providing clean and safe CBD and THC products. In the company’s press release dated January 13, 2021, it reported system-wide sales of Platinum-branded products exceeding $2.8 million for the first week of January alone.
• High Times®: In June 2020, the company acquired the licensing rights and branding of High Times dispensaries and High Times cannabis-based CBD and THC products in Michigan, Illinois and Florida. The company also acquired branding of High Times hemp derived CBD products nationally in the United States carrying the Culture® brand.
• Mid-American Growers: Mid-American began as a family operation in 1971 in Granville, Illinois. The original 8-acre greenhouse has expanded to a 3.6-million-square-foot, state-of-the-art technology and science facility under glass. Mid-American’s product offerings include its CBD Icy Relief Salve, CBD Icy Relief Roll-on and CBD Gummies.

Retail Focus

Red White & Bloom is working to establish a significant retail presence across multiple jurisdictions. In Michigan, the company is invested in and has the rights to acquire (subject to regulatory approvals) a licensed operator that controls the assets of 18 dispensary locations throughout the state. Red White & Bloom is also pursuing opportunities in Florida aimed at making its proposed retail footprint compelling and attractive to the majority of cannabis consumers within each state.

Cultivation

Red White & Bloom is focused on standardization and quality, with everything guided by a relentless commitment to the highest standards. The company acquired a 3.6-million-square-foot standardized facility dedicated to helping it achieve premium value for the products it intends to cultivate.

As it continues to expand, the company remains committed to the practices that have guided its success in the past, including:

• A top-down approach to cultivation developed under the guidance of PhDs with expertise in growing principles, SOPs and, most importantly, the science behind it all.
• Commitment to exceeding the requirement of the states in which it operates. The company cut its teeth under the world’s first national cannabis purity regime – a regime that most new markets use as a benchmark – so quality is in its DNA.
• Science-driven production methods supported by automated, perpetual, standardized operations that enable craft cannabis-like quality at an industrial scale.

Footprint

Assuming completion of the currently proposed investments and acquisitions, Red White & Bloom will be among the cannabis market’s largest companies, joining the ranks of a select few multi-state operators dominating the industry. Red White & Bloom currently has assets (closed and in closing stages) in Michigan, Illinois, Florida, California, Oklahoma and Massachusetts.

The company’s strategic acquisition and super state operator model, combined with its commitment to top-quality product and service, position it to become a leading player in the North American cannabis market.

When evaluated beside competitors in the cannabis space, Red White & Bloom boasts an extremely attractive valuation. While large cap cannabis firms serving North American markets averaged enterprise-value-to-EBITDA multiples of 14.9x as of December 2020, Red White & Bloom’s enterprise multiple was just 3.4x, as noted in the company’s latest investor deck.

In 2020, the cannabis market worldwide was valued at $24.6 billion. This amount is expected to expand at a CAGR of 14.3% from 2021 to 2028, resulting in a market size of $84 billion in 2028 (https://nnw.fm/f09ZL). Of the 2020 valuation, the largest revenue share (91.1%) was attributed to North American consumers (https://nnw.fm/vObW6).

Management Team

Brad Rogers is the CEO and Executive Chair of Red White & Bloom. He is a visionary for the future of cannabis and CBD products in the United States market, with a proven track record of building successful and profitable businesses in the rapidly expanding and new economic sector. Mr. Rogers was a part of the team that built one of the first commercially scaled production facilities in the world for medicinal cannabis. He also served as President for one of the leading licensed producers in Canada. Both of his ventures were successful, with a combined market cap of $2 billion.

Michael Marchese is the company’s Co-Founder and Marketing Advisor. He has played a crucial role in its development and organization, overseeing capital raises, acquisition strategy and brand identity. Mr. Marchese has a strong reputation and presence in the cannabis industry. He also co-founded and directed the branding of Aleafia Health Inc., which he continues to counsel. Through his branded company, Marchese Design, he has served as a highly trusted counselor to top-level execs, including C-Suite level employees, offering insights into the process of creating, building and maintaining brand identities.

Theo van der Linde is the CFO and Director of Red White & Bloom. He is a Chartered Accountant with 20 years of experience in finance, administration and public accounting. The experience he has acquired spans multiple industries, including mining, oil & gas, financial services, retail and manufacturing. For the last nine years, he has primarily focused his career on the mining industry, working with junior exploration and producing mining companies at various stages of growth in several jurisdictions. Mr. van der Linde is also the current President of Executive Management Solutions Ltd.

Red White & Bloom Brands Inc. (RWBYF), closed Monday's trading session at $0.6975, off by 4.4521%, on 221,496 volume with 155 trades. The average volume for the last 3 months is 221,496 and the stock's 52-week low/high is $0.33/$1.65.

Recent News

• Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) - 420 with CNW - Federal Report Finds More Financial Institutions Are Working with Cannabis Businesses
• Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) Receives Adult Use Prequalification Status in Michigan; Sanderson Facility to Help Satisfy Edibles Market Demand
• 420 with CNW - What Indiana Residents Need to Know Before Buying Cannabis in Illinois

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF)

The QualityStocks Daily Newsletter would like to spotlight Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF).

The National Institute on Drug Abuse is financing research on the use of magic mushrooms in managing cigarette addiction. The top federal drug agency recently awarded the grant to researchers from the University of Alabama at Birmingham, New York University and Johns Hopkins University to investigate how psilocybin could help individuals quit smoking cigarettes. As more academic institutions take up the challenge of conducting scientific studies on psychedelics, the strides made by for-profit companies such as Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) will take on even greater meaning due to the rapidly growing body of science-backed information about these compounds.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) is a pharmaceutical company focused on developing clinical-stage compounds for diseases with high unmet medical needs through accelerated regulatory pathways.

The company was founded in 2019 and is headquartered in San Diego, California.

Innovative Drug Pipeline

Tryp’s current focus is on advancing its two drug development platforms: its Psilocybin-for-Neuropsychiatric Disorders (PFN™) program targeting fibromyalgia, eating disorders and chronic pain conditions; and razoxane for soft tissue sarcomas. The company intends to explore opportunities to monetize these platforms after generating Phase 2b clinical data.

The company’s development plans cover three strategic initiatives:

• Develop: Tryp intends to utilize the FDA’s 505(b)(2) regulatory pathway with available third-party preclinical data to shorten the timelines and lower the cost of its development programs.
• Protect: Tryp plans to utilize regulatory exclusivity, patents, trade secrets and proprietary know-how to protect the commercial lifespan of its drug candidates.
• Monetize: Tryp intends to seek out licensing, acquisition and co-development opportunities for drug candidates following their Phase 2 stages of development.

PFN™ Program

Through its PFN™ program, the company is focused on developing psilocybin-based drug therapies for certain neuropsychiatric disorders that have distinct advantages over other drugs currently on the market or in development. These advantages include:

• Increased efficacy
• Natural blood-brain barrier penetration
• Enhanced safety and toxicity profiles
• Reduced risk of abuse
• Reduced risk of addiction

Tryp’s PFN™ program features its lead drug candidate, TRP-8802. The company’s initial indication for TRP-8802 is fibromyalgia.

Fibromyalgia is believed to be a neurosensory disorder characterized in part by abnormalities in pain processing by the central nervous system. The three drugs with FDA approval for the treatment of fibromyalgia are Pregabalin (Lyrica®), Duloxetine (Cymbalta®) and Milnacipran (Savella®), which are only effective for a portion of patients suffering from the condition.

Tryp plans to seek FDA approval to proceed directly to Phase 2 clinical trials evaluating TRP-8802 as a treatment for fibromyalgia based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802.

Tryp’s pipeline of indications for TRP-8802 also includes eating disorders and certain forms of chronic pain. The company expects to initiate Phase 2a clinical trials in these areas in 2021.

Tryp recently partnered with Albany Molecular Research Inc. (“AMRI”) for the manufacture of the company’s synthetic psilocybin using proprietary methods. AMRI has initiated the process of manufacturing a 200g non-GMP demonstration batch of psilocybin and will produce a batch of GMP psilocybin in mid-2021. As the holder of the Drug Master File, Tryp expects to be the only U.S.-based manufacturer of synthetic psilocybin in the industry.

Razoxane

Tryp’s second drug candidate, TRP-1001 (razoxane), is being developed as a treatment for soft tissue sarcomas and has been evaluated in multiple Phase 2 clinical trials conducted by clinicians unaffiliated with Tryp. The company believes that existing clinical data regarding razoxane will likely allow TRP-1001 to be studied in a Phase 2 trial without the need for extensive preclinical or Phase 1 trials.

Sarcomas are rare tumors that are derived from connective tissues in the body and comprise 7% of all cancers in children. In 2018, an estimated 13,000 new cases of soft tissue sarcoma were diagnosed, with the tumors resulting in over 5,000 deaths during that year in the United States alone (https://ibn.fm/nWOGq).

Market Outlook

With its drug development programs targeting multiple indications, Tryp is well positioned to capitalize on growth opportunities spanning a range of therapeutic markets. The global oncology drugs market, in particular, represents a sizable opportunity.

In 2018, oncology indications accounted for 25% of all drug sales, representing approximately $151 billion in market revenues. By 2024, spending on oncology-targeted therapeutics is expected to top $200 billion and account for roughly 30% of total drug sales, according to a study by Cowen Equity Research (https://ibn.fm/9iZhM).

Valued at $764 million in 2020, the global fibromyalgia treatment market presents unique opportunities for development due to the limited number of approved therapies. With treatment trending upward, the market is expected to grow at a CAGR of 9.2% and reach $1.4 billion in value by 2027 (https://ibn.fm/G66e7).

Management Team

Greg McKee is the Chairman and CEO of Tryp Therapeutics. He has more than 20 years of life sciences management and venture investment experience that he brings to the company. Before taking his role at Tryp, he was the founder of Torrent Ventures, an early-stage digital health and medical technology venture fund. Mr. McKee also served as the CEO of CONNECT, the largest Southern California start-up accelerator. Before this, he was the chairman, president and CEO of then publicly traded Nventa Biopharmaceuticals, which successfully merged with Akela Pharma. Mr. McKee earned a B.A. in Economics from the University of Washington, an M.A. in International Studies from The Joseph H. Lauder Institute, and an MBA from the Wharton School at the University of Pennsylvania. He has been a member of the Young President’s Organization (YPO) since 2006.

James Gilligan, Ph.D., is the company’s President and Chief Science Officer. He has over 35 years of experience in the life sciences industry, including research and development, clinical development, international regulatory affairs and manufacturing. Before joining Tryp, Dr. Gilligan was the Co-Founder and Managing Partner of The Bracken Group, a life sciences consulting firm. He was also the Co-Founder of Unigene Laboratories, which develops technology for the recombinant manufacture of peptide hormones. Dr. Gilligan received his Ph.D. in Pharmacology from the University of Connecticut and a MSIB from Seton Hall University. He continued his post-graduate education at the Roche Institute of Molecular Biology.

Tom D’Orazio is the Chief Operating Officer of Tryp Therapeutics. He has extensive experience in leading the development and commercialization of vaccines, drugs, radiopharmaceuticals and biologics. His prior leadership experience has been in commercial planning, marketing, partnership and business development roles. He was formerly the CEO of ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA), where he led the transition from a private company to a public one. He co-founded and served as CEO of Superna Life Sciences, a specialty-pharma company focusing on niche drugs for cancer patients in Canada. Mr. D’Orazio has an MBA from Vanderbilt University with a primary focus in both finance and marketing and a B.Sc. in chemistry from Loyola University of Chicago.

Luke Hayes is the company’s Chief Financial Officer. He has played an active role in the life science industry for over 20 years with technology transfer, venture capital and finance experience. His career started with business development for Dow Chemical (NYSE: DOW), with responsibility for pharmaceutical customers such as Eli Lilly and AbbVie. Mr. Hayes has spent more than a decade doing venture capital investing while supporting companies as a director and advisor. He earned a B.S. in Chemical Engineering from Brigham Young University and an MBA from the UCLA Anderson School of Management.

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF), closed Monday's trading session at $0.3377, off by 0.764032%, on 106,701 volume with 26 trades. The average volume for the last 3 months is 106,701 and the stock's 52-week low/high is $0.2701/$1.04.

Recent News

• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) - NIDA Awards Grant for Research on Potential of Psilocybin in Treating Cigarette Addiction
• Phantom Limb Pain: Causes and How a Physical Therapist May Help
• Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Achieves Most Important Milestone Yet with Submission of IND Application for Phase 2a Clinical Trial

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF)

The QualityStocks Daily Newsletter would like to spotlight Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF).

Mind Cure Health (CSE: MCUR) (OTCQX: MCURF), a leader in advanced proprietary technology and research for psychedelics, has so far reached several key milestones in 2021. According to a recent article, these include: “raising $23 million in a bought deal short form prospectus public offering that closed in February this year. On the technology side, MCURF launched the minimum viable product (‘MVP’) of iSTRYM in Q3 2021. On the drug development and research side, the company synthesized ibogaine and has launched the second stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. The company has also filed patent applications for two routes of chemical synthesis of ibogaine.” Additionally, in a recent Bell2Bell podcast episode, MCURF CEO and President Kelsey Ramsden noted that although ibogaine, a psychedelic drug, is very chemically complex and difficult to build in the lab, the MCURF team was able to synthesize it fully. For the remainder of 2021, “The company intends to spend about six months iterating the iSTRYM product in anticipation of a full commercial product launch in Q1 2022. Mind Cure Health also aims to scale up its ibogaine production to provide the psychedelic drug to researchers. Further, it is working on new research initiatives.” To view the full article, visit: https://ibn.fm/rDsl0

Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (“MINDCURE”) is a diversified life sciences company at the forefront of the mental health industry. The company is currently developing digital therapeutics and researching psychedelic compounds, while innovating and commercializing new ways to promote healing and improve mental health.

MINDCURE’s research and digital therapeutics technology supports access to safe, science-based, evidence-backed psychedelic-assisted therapies globally. With hundreds of millions of people suffering from mental illnesses worldwide and an estimated $1 trillion in lost productivity per year, psychedelics offer promising alternatives for healing. This medical need has been amplified by the COVID-19 pandemic. According to the Centers for Disease Control and Prevention, 40 percent of U.S. adults reported struggling with substance abuse or mental health issues during the pandemic.

MINDCURE is uniquely positioned to address these medical needs. By concentrating on both technology and research, the company is focusing on near-term revenue generation, targeting a longer-term, blue sky horizon and hedging against regulatory unknowns with a scalable, adaptive model. MINDCURE’s software-as-a-service (SaaS) platform, iSTRYM, scales globally and services every psychedelic medicine without the capital-intensive drag of clinic scale-out costs. The company plans to first enter the market for psychedelic-assisted psychotherapy, then to move into the larger fields of technologically undisrupted psychotherapy and psychiatry.

Technology

Digital therapeutics include health interventions delivered through a smart device to induce a behavioral change in the patient. The global market is focused on simplifying behavioral change and empowering consumers to take charge of their own health. iSTRYM is the company’s AI-driven software platform that enables personalized and quantified outcomes in psychedelic therapy. The SaaS platform modernizes care, taking it from manual to digital and bringing better treatment outcomes for patients and therapists while lowering costs for insurers.

iSTRYM offers clinicians direct access to global, science-backed, evidence-based protocols, integration plans, insights into client journeys, and real-time assessments for personalized care. Patients access the platform on their smart devices, enjoying transparency into their wellness journeys, personalized care resources, and optimized relationships with their practitioners. The minimal viable product (MVP) of the software is being launched in Q3 2021. MINDCURE targets a Q1-Q2 2022 commercial product launch.

Research

In June 2021, the company announced it had completed the first stage of manufacturing pharmaceutical-grade synthetic ibogaine to be used in clinical research. In July, MINDCURE announced it had filed U.S. Provisional Patent applications for the company’s first full synthetic routes to create ibogaine. The company’s pharmaceutical grade ibogaine would provide researchers access to a sustainable, high-quality, reliable, and consistent supply of the psychedelic drug.

The company is also actively researching ibogaine as a potential treatment for Traumatic Brain Injury and related conditions. Preliminary data show the drug may also have promise as a treatment for neuropathic pain and migraines. In addition, research indicates ibogaine may help repair and rewire the brain’s neural pathways, making it potentially useful in the treatment of addictions.

Market Outlook

MINDCURE actively develops technology, conducts research, and distributes products in several market spaces. The global market for digital therapeutics is projected to grow to $6.9 billion by 2025, from an estimated $2.1 billion in 2020. In North American alone, the market is forecast to reach $5 billion by 2025.

The market for treatment of drug, alcohol and other addictions is estimated to be worth $38.2 billion in 2021, with a forecast CAGR of 5.2 percent for the next several years. The global market for the treatment of neuropathic pain is forecast to account for $9 billion by 2027, while drug treatment for migraines is expected to have a value of $2.1 billion by 2025.

Management Team

Kelsey Ramsden is President and CEO of MINDCURE. She has 15 years of experience founding, scaling, and operating innovative companies across Canada and the Caribbean. She has built multiple eight-figure businesses and twice been named Canada’s Top Female Entrepreneur. She holds a seat on the Entrepreneurship Council for the University of Western Ontario, where she is also a faculty member. She has an MBA from the Richard Ivey School of Business at the University of Western Ontario.

Dr. Joel Raskin is the Chief Medical Officer at MINDCURE. He is a psychiatrist and academic with 20 years international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch and commercialization with Eli Lilly & Co., where, as Senior Director, he led the medical affairs team for Alzheimer’s disease diagnostics and therapeutics. He earned his medical degree from the University of Toronto and is a Fellow of the Royal College of Physicians and Surgeons of Canada in Psychiatry.

Tarik Lebbadi is the COO at MINDCURE. He has more than 13 years of international operational experience. Before joining the company, he led the medical division of Johnson & Johnson in Morocco. He holds a BA in mathematics and computer science from Ripon College and an MBA from IESE Business School in Barcelona, Spain.

Geoff Belair is the CTO at MINDCURE. He has 30 years of experience working in highly regulated industries, including fintech and banking. He was the senior architect and creator of the Integration Services Team at banking solutions company Fincentric Corporation. Before joining MINDCURE he was Vice President of Information Technology at Westland Insurance.

Michael Wolfe, CPA CA, is MINDCURE’s CFO. He has 30 years of experience in finance, accounting, private equity, and business valuation. He was previously CFO of Baylin Technologies Inc., as well as CFO of several mid-market Canadian companies, including Masstech Group Inc. He was General Partner at VenGrowth Capital Partners Inc. He holds an MBA from McMaster University and a BA in business and economics from the University of Western Ontario.

Daniel Herrera is Vice President of Growth & Strategic Partnerships at MINDCURE. He is a former pharmaceutical executive with extensive experience in highly regulated industries. He is experienced with medical affairs, product development and product licensing, negotiations with public and private payers, GPOs, and pharmacy buyers, as well as strategic partnerships resulting in high-value M&A transactions. He is a graduate of McGill University and the University of Montreal and holds an MBA from the John Molson School of Business at Concordia University.

Mind Cure Health Inc. (OTCQX: MCURF), closed Monday's trading session at $0.254, off by 0.878049%, on 199,776 volume with 71 trades. The average volume for the last 3 months is 199,776 and the stock's 52-week low/high is $0.2456/$0.8584.

Recent News

• Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) - BioMedNewsBreaks - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) Achieves Several Key Milestones in 2021
• Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Launches The Desire Project to Promote MDMA-Assisted Psychotherapy Treatment for HSDD
• InvestorNewsBreaks - Mind Cure Health Inc. (CSE: MCUR) (OTCQX: MCURF) (FRA: 6MH) Commences Trading on the OTCQX Best Market

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC)

The QualityStocks Daily Newsletter would like to spotlight BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC).

• BevCanna is rapidly increasing its footprint within the Canadian functional beverages market
• The company has recently entered into a sales service agreement with Velvet Management Inc., Canada’s leading cannabis sales agency
• BevCanna has also separately announced that its highly sought-after products will now be distributed by the British Columbia Liquor Distribution Branch, Canada’s fourth largest provincial cannabis product retailer
• The moves bode positively for BevCanna in consolidating its position as a preeminent white label partner operating within the Canadian cannabis market

BevCanna Enterprises (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC), a diversified health & wellness beverage and natural products company developing and manufacturing a range of alkaline, plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients has recently announced a series of new corporate developments, designed to further broaden its commercial prospects moving forward.

BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) is a diversified health & wellness beverage and natural products company focused on developing and manufacturing a range of plant-based and cannabinoid beverages and supplements for both in-house brands and white-label clients. The BevCanna team boasts decades of experience creating, manufacturing and distributing iconic brands that resonate with consumers on a global scale.

BevCanna’s distribution network features more than 3,000 points of retail distribution through the company’s market-leading TRACE brand, its Pure Therapy natural health and wellness e-commerce platform, its fully licensed Canadian cannabis manufacturing and distribution network and its partnership with #1 U.S. cannabis beverage company Keef Brands.

Based in British Columbia, Canada, BevCanna was founded in 2017.

End-to-End Turnkey Beverage Manufacturing Solutions

BevCanna is a manufacturer of traditional and cannabis-infused beverage brands serving a growing roster of white-label clients, in addition to operating a portfolio of in-house and partner brands. The company offers a full-service white label beverage manufacturing solution.

• Processing – At its state-of-the-art beverage manufacturing facility, BevCanna partners with industry leaders specializing in crude extraction, refinement, purification and solubility conversion to provide high-quality water-immiscible emulsions that maximize bioavailability, clarity and taste.
• Spring Water – BevCanna directly owns a pristine naturally alkaline spring water aquifer in British Columbia.
• Product Development – BevCanna leverages its expertise to develop captivating flavors based on category and consumer insights in order to enhance product positioning.
• Packaging – A variety of packaging options are offered by BevCanna, including beverage and nutraceutical formats such as PET, aluminum and glass, available in a variety of standard and custom sizes and shapes.
• Beverage Manufacturing: Traditional & Cannabis Facilities – The company’s 40,000-square-foot beverage manufacturing facility is HACCP (Hazard Analysis Critical Control Point) Certified. The facility’s capabilities include blow molding, dosing, carbonation options, filling and capping, pressure sensitive and shrink-sleeve label applications, flash pasteurization, QA testing and packing/palletizing for shipment.

Pure Therapy, TRACE and Partner Brands

BevCanna’s in-house brands include Pure Therapy and TRACE.

Pure Therapy is a direct-to-consumer e-commerce brand that markets a range of natural health products, including nutraceuticals and hemp-based cannabidiol (CBD) products, throughout North America and Western Europe.

Pure Therapy has secured orders from over 23,000 customers since its inception in 2017. BevCanna expects strong growth through Pure Therapy over the next 12 months driven by new product integration, accelerated growth of existing products and its marketing team’s e-commerce expertise.

TRACE products feature the Naturo Group’s proprietary plant-based fulvic and humic mineral formula, sourced from deep within the Rocky Mountains of interior British Columbia. These unique and ancient minerals provide wellness properties that include iron, magnesium, calcium, potassium and many other minerals no longer found in our food chain at adequate levels.

Research suggests that the proprietary fulvic and humic organic compounds found in TRACE products could offer a number of key benefits, including promoting gut health, immune function, cognitive performance and whole-body wellness.

TRACE products include Natural Alkaline Spring Water, Plant-Based Mineralized Spring Water, Natural Flavor Sparkling Spring Water, Plant-Based Mineral Concentrate with Vitamin D and Plant-Based Mineralized Immune Support Shots.

In addition to its in-house brands, BevCanna provides white-label services to a number of partners in its space. BevCanna’s current portfolio of brand partnerships includes #1 U.S. cannabis beverage brand Keef (cannabis-infused classic soda) and BLOOM (live resin & high-end extracts). BevCanna also has multiple white label agreements to co-manufacture branded beverages.

Market Outlook for Cannabis-Infused Beverages

In 2018, the cannabis-infused beverage market was valued at $901.8 million. The market is expected to grow during the forecast period of 2019 to 2025 at a CAGR of 17.8%, resulting in a market value in excess of $2.84 billion by 2025, according to Grand View Research (https://ibn.fm/VkJfH).

The projected growth is largely attributed to the legalization of recreational and medical marijuana in multiple jurisdictions. Cannabis-infused beverages are uniquely positioned to provide an alternative to a large portion of the edibles market, including items such as chocolates, cookies, gummies and other types of confectionery pieces.

Management Team

Marcello Leone is the CEO and Founder of BevCanna. He is also the founder of Naturo Group and the TRACE brand.

John Campbell is the CFO and CSO of BevCanna. He has over 30 years of experience in the investment industry, including time with TriView Capital Ltd.

Keith Dolo is the company’s Executive Management Advisor, having previously served as CEO and Executive Chairman of Sproutly Inc. Previously, he served for over 13 years with Robert Half (NYSE: RHI), an S&P 500 company, specifically in the role of Vice President for the last eight years.

Melise Panetta is the company’s President. She is an accomplished senior marketing and sales executive with extensive experience leading organizations such as SC Johnson, General Mills (NYSE: GIS) and PepsiCo (NASDAQ: PEP). Ms. Panetta has nearly 15 years of deep marketing and sales expertise.

Raffael Kapusty is the company’s Vice President of Sales & Insights. She is an accomplished CPG industry leader with more than 25 years of experience in both the Canadian and U.S. retail spaces. With a solid foundation at ACNielsen Canada (NYSE: NLSN), Ms. Kapusty has developed a deep understanding of the CPG space, working with over 100 leading Canadian & global CPG manufacturers. She has also held senior category and key account management roles at Kroger (NYSE: KR), SC Johnson and Unilever Canada (NYSE: UL).

Bill Niarchos is the company’s Vice President of Sales & Sales Operations. He has over 20 years of experience in the CPG goods industry/retail environment. In his most recent role as Director of Sales with Bayer Consumer Health, Mr. Niarchos managed the strategic direction and growth of Loblaw & SDM. Prior to his position with Bayer (ETR: BAYN), Mr. Niarchos held a number of progressive roles at Colgate Palmolive (NYSE: CL) for more than 14 years.

Japheth Noah is the company’s Head of Quality Assurance. He is an Oxford and MIT educated quality and regulatory manager with over 15 years of experience in the beverage, pharmaceutical, natural health and medical industries.

Keith Stride is the company’s Creative Director. He has 25 years of experience in marketing and advertising, including time in a CMO role with Hemptown USA. Mr. Stride is internationally recognized for building high-profile brands, including Rogers (NYSE: RCI), TD Bank (NYSE: TD), Best Buy (NYSE: BBY), Whistler-Blackcomb and RBC (NYSE: RY).

BevCanna Enterprises Inc. (OTCQB: BVNNF), closed Monday's trading session at $0.2228, off by 7.1667%, on 177,088 volume with 78 trades. The average volume for the last 3 months is 177,088 and the stock's 52-week low/high is $0.1575/$1.20.

Recent News

• BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) - BevCanna Enterprises Inc. (CSE: BEV) (OTCQB: BVNNF) (FSE: 7BC) Expands Its Distribution Footprint Across Canada; Announces Series of Retail Partnerships
• 420 with CNW - Canadian Marijuana Sector Demands Changes to Policies Stifling Infused Drinks
• Rising Natural Wellness Momentum Fuels Cannabis Market

Asia Broadband Inc. (OTC: AABB)

The QualityStocks Daily Newsletter would like to spotlight Asia Broadband Inc. (AABB).

Precious metals can be traded through various multiple security classes, such as exchange traded funds, funds, options, futures and metal trading. The metals are usually classified as commodities. The most popular and most heavily traded commodities for investments globally, namely silver and gold, provide a lot of trading opportunities with high liquidity. This means that arbitrage opportunities exist in the trading of precious metals, just as with other tradable assets. At the moment, producers such as Asia Broadband Inc. (OTC: AABB) and others are ensuring that the existing demand for gold is met, thereby preventing the metal from experiencing abnormal volatility.

Asia Broadband Inc. (OTC: AABB) is a resource company focused on the production, supply and sale of precious and base metals, primarily to Asian markets.

The company utilizes its specific geographic expertise, experience and extensive industry contacts to facilitate its innovative distribution process from the production and supply of precious and base metals in Mexico to client sales networks in Asia. This vertically integrated approach to sales transactions differentiates Asia Broadband from its competitors in the mining space.

Development Program in Colima, Mexico

In October 2020, Asia Broadband announced its acquisition of a high potential mineral property in the state of Colima, Mexico. Per the press release, previous geophysics and groundwork have revealed strong indications of significant mineralization in multiple sectors of the property.

The company recently began the construction of exploration and development facilities and infrastructure roads on its Colima property, and plans are underway to extend previous geophysics and groundwork on the property. In January 2021, Asia Broadband announced its allocation of $10 million for the initial development program, with the aim of accelerating operations at the Colima site toward production.

Positioned in a major gold-iron-copper production area, the company’s Colima property is situated approximately 25 kilometers east of the Pena Colorada mine in Minatitlan, Mexico. It is advantageously located, with direct access to main Highway #3, and the property also has an essential natural water supply.

AABB Gold Token

In December 2020, Asia Broadband announced its entry into a definitive development agreement with Core State Holdings Corp., a digital assets and crypto wallet creator, to produce a white label gold-backed cryptocurrency coin. The AABB Gold token is an ERC-20 token being developed on the Ethereum blockchain.

In a February 2021 news release, the company provided a development update on the cryptocurrency token, noting that Core State Holdings Corp. “is continuing to modify the set-up and move through the final stages of testing of the iOS and Android AABB Wallet applications, including the implementation of an application interface to allow users to see the real-time exchange rate of gold that backs the price of the AABB Gold token set at one-tenth of a gram or approximately $5.80 USD.”

Core State Holdings Corp. has also continued to enhance www.AABBGoldToken.com, which the company notes will be the go-to knowledge base for all information concerning the soon-to-be launched AABB Wallet and AABB Gold token.

AABB’s primary goal for the token is to become a worldwide standard of exchange – secured and trusted with gold backing – by expanding circulation and targeting large population and high growth markets globally, including China and East Asia.

Asia Broadband Inc. (AABB), closed Monday's trading session at $0.112665, off by 1.0408%, on 16,120,569 volume with 936 trades. The average volume for the last 3 months is 16.121M and the stock's 52-week low/high is $0.0026/$0.659.

Recent News

• Asia Broadband Inc. (OTC: AABB) - Factors Affecting Precious Metals Arbitrage
• An Overview of Gold Production in 2020
• InvestorNewsBreaks - Asia Broadband Inc. (AABB) Announces LOI to Form JV with Mexico Gold Mine

InnerScope Hearing Technologies Inc. (OTC: INND)

The QualityStocks Daily Newsletter would like to spotlight InnerScope Hearing Technologies Inc. (INND).

• InnerScope Hearing Technologies is a direct-to-consumer manufacturer, distributor, and retailer of hearing aids and assorted hearing-related products
• The White House has recently published initiatives designed to de-regulate the hearing aid market, including allowing hearing aids to be purchased over the counter as well as negating the need for the devices to be prescribed by a medical professional
• InnerScope has introduced a series of free, self-administered hearing screening kiosks which can help consumers identify hearing loss and the severity of their hearing loss as well as the type of loss, and subsequently, recommend the best hearing aid for their particular case
• InnerScope has recently launched its product range on FSAstore.com, HSAstore.com, and WellDeservedHealth.com, as well as its own e-commerce site, MyHearIQ.com.

Although approximately 28.8 million Americans could benefit from wearing hearing aids today, fewer than 16 percent have ever used them. In fact, studies have shown that most people wait nearly 15 years from the time they know they have hearing loss until they actually purchase their first hearing aids – often citing elevated device prices as a barrier to purchase (https://ibn.fm/xFSCM), even though untreated hearing loss could be a precursor to more significant mental health problems, including depression, social isolation, and serving as an early indicator of Alzheimer’s disease. InnerScope Hearing Technologies (OTC: INND), a manufacturer and distributor/retailer of DTC, FDA registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (“PSAPs”), as well as various hearing-related treatments, has sought to target this issue, thereby improving the quality of life of the 70 million people in North America and the 1.5 billion people worldwide suffering from hearing-related issues.

InnerScope Hearing Technologies Inc. (OTC: INND) is a Nevada corporation incorporated on June 15, 2012, with its principal place of business in Roseville, California. The company was initially started in 2006 – operating as InnerScope Advertising Agency Inc. – to provide advertising and marketing services to retail establishments in the hearing device industry. On August 25, 2017, the company changed its name to InnerScope Hearing Technologies Inc. to better reflect its current direction as a hearing health technology company that manufactures, develops, distributes and sells numerous innovative hearing health-related products, hearing treatments and hearing solutions, direct-to-consumer (DTC) through a scalable business model.

The company is a manufacturer and a distributor/retailer of DTC, FDA (U.S. Food and Drug Administration) registered, Bluetooth app-controlled hearing aids and personal sound amplifier products (PSAPs), hearing-related treatment therapies, doctor-formulated dietary hearing supplements, proprietary CDB oil for treating tinnitus and assorted hearing and health-related products targeting approximately 70 million Americans suffering from hearing-related problems. The company’s mission is to improve the quality of life of the 70 million people in North America and the 1.5 billion people worldwide who suffer from hearing impairment and/or hearing-related issues.

The management team of InnerScope is applying decades of industry experience and believes it is well-positioned, with its innovative in-store point-of-sale Free Self-Check Hearing Screening Kiosks (“Hearing Kiosks”), to directly benefit when the Over the Counter (OTC) Hearing Aid Act (the “OTC Hearing Aid Law”) is enacted (expected in late 2021 based on the President’s Executive Order issued on July 9, 2021) The OTC Hearing Aid Law allows OTC hearing aids for perceived mild-to-moderate hearing losses to be sold in retail stores without having to see a professional. InnerScope’s Hearing Kiosk is designed to help the tens of millions of Americans with undetected/untreated mild-to-moderate hearing loss treat themselves with the company’s easy, convenient and affordable OTC hearing aids, in-store and/or online.

Industry Game-Changer – New Emerging Market with 48 Million Potential Customers

The following is sourced from The White House Fact Sheet detailing an Executive Order from President Biden aimed at saving Americans with hearing loss thousands of dollars by allowing hearing aids to be sold over the counter at drug stores:

“Hearing Aids: Hearing aids are so expensive that only 14% of the approximately 48 million Americans with hearing loss use them. On average, they cost more than $5,000 per pair, and those costs are often not covered by health insurance. A major driver of the expense is that consumers must get them from a doctor or a specialist, even though experts agree that medical evaluation is not necessary. Rather, this requirement serves only as red tape and a barrier to more companies selling hearing aids. The four largest hearing aid manufacturers now control 84% of the market.”

On July 9, 2021, President Biden noted the following in reference to his Executive Order relating to hearing aids:

“Right now, if you need a hearing aid, you can’t just walk into a pharmacy and pick one up over the counter. You have to get it from a doctor or a specialist. Not only does that make getting hearing aids inconvenient, it makes them considerably more expensive, and it makes it harder for new companies to compete, innovate and sell hearing aids at lower prices.”

“As a result, a pair of hearing aids can cost thousands of dollars. That’s a big reason why just one in seven Americans with hearing loss actually use a hearing aid.”

InnerScope Game-Changers

For InnerScope, this Executive Order could present a significant opportunity. The company is uniquely positioned with a number of strategic advantages and offerings in the space, including:

• First to Market: Free self-check hearing screening kiosks deployed in national pharmacy chains, big-box retailers & national and local groceries chains
• Online Hearing Screening Tests: For national retailers to use their websites to attract more customers in conjunction with the company’s in-store hearing kiosks
• The HearIQ App for iOS and Android users: Offers a free self-check hearing test and provides a user control function for InnerScope’s Bluetooth app-controlled self-adjusting rechargeable hearing devices
• Customer Monthly Subscription Model: Offering the lowest, most affordable monthly payment options (as low as $42 per month for pair of rechargeable, app-controlled hearing aids) for consumers to purchase hearing aids and receive free upgrades every two years.

The In-Store Hearing Screening Kiosks and Online Free Hearing Screening Tests

Innerscope’s hearing screening kiosk and online hearing screening tests offer free self-check hearing evaluation using the world’s first “Hearing Triage” artificial intelligent pattern recognition software, which has a unique ability to classify both level (degree of loss) and pattern (type of loss). In addition, the software can detect the probable location of the hearing problem and its degree of severity.

The tests are developed as a hearing wellness tool to help track hearing ability and (if tests results indicate a hearing loss) make recommendations for in-store point of sale or online purchase of one of InnerScope’s hearing devices, as well as providing recommendations to see one of the professionals in InnerScope’s local contracted network of hearing health care experts for further follow-up testing if necessary. The software also generates an audiometric report which is instantly emailed to the customer.

The HearIQ App

InnerScope is the creator of the HearIQ App, which offers free self-check hearing tests and provides a user control function for InnerScope’s line of Bluetooth app-controlled self-adjusting rechargeable hearing devices. InnerScope developed the free hearing test part of the HearIQ App to help with the early detection of hearing loss for the 1.5 billion people worldwide who have untreated hearing loss or some form of hearing issues that may be undetected and do not have access to a computer for InnerScope’s online hearing screening test.

Hearing Aid Products

Through its dedicated online store, MyHearIQ.com, InnerScope offers affordable, direct-to-consumer, Bluetooth app-controlled, self-adjusting hearing technology to empower consumers to take control of their hearing care. InnerScope’s hearing technology allows the customer in less than 10 minutes using any smartphone to personalize each hearing device to their hearing needs using an onboard in-ear custom-fit self-testing feature through the HearIQ App.

InnerScope is shifting hearing health care from traditional brick-and-mortar hearing care clinics to customers’ homes by providing a unique solution to give customers top quality, affordable access to hearing aids without the need to see a hearing professional or go to a hearing care clinic. As a result, InnerScope can deliver the same level and quality of hearing technology and expert support for the customer from their homes at a fraction of the cost of traditional channels. All InnerScope hearing aid devices are medical-grade and available with professional remote programming and support services from one of the company’s licensed hearing professionals through the HearIQ App.

Hearing & Tinnitus Dietary Supplements

InnerScope has developed a proprietary line of doctor-designed hearing & tinnitus dietary supplements to help people with hearing problems protect themselves from future hearing issues. There are currently three types of formulas to choose from, including Ear-Ring Relief for the 60 million Americans who suffer from tinnitus, HearingVite + Memory Boost for people with hearing loss and cognitive issues, and HearingVite + Multivitamin for maintaining proper hearing health and levels of nutrients.

Complete Line of Hearing Health Care Products

InnerScope offers a brand label of assorted ear care and hearing aid maintenance products. In support of overall ear health and ensuring maximum performance from its hearing aids and comfort for its customers, InnerScope provides a whole line of care items, including cleaning kits, wipes, spray and drying tablets, ear cleaner for wax removal, a natural lubricant agent for new hearing aids and hydrating lubricating ear gel.

Verified Wholesale and Direct-to-Consumer Sales

InnerScope is a verified wholesaler with Walmart for premium affordable direct-to-consumer hearing aids, personal sound amplification and hearing health accessories. InnerScope also created an easy shopping experience for its hearing and tinnitus vitamins through Walmart and Amazon Prime. With new partnerships in the works, the company aims to add other online and brick-and-mortar establishments to its vitamin distribution network in the future.

Hearing Aid Market Outlook

The global hearing aid market is expected to reach $11.02 billion by 2028, growing at a CAGR of 7.4% during the forecast period. This marks a significant increase from the $6.47 billion value reported in 2020, an increase largely driven by innovations being made in hearing aid technology (https://ibn.fm/bRWUb).

As a leading wholesale provider and direct-to-consumer business, InnerScope is positioned to disrupt the global hearing aid market. Its partnerships with some of the United States’ largest retail distributors and wholesalers are only strengthening the company’s position within the industry.

Management Team

Matthew Moore is the President and CEO of InnerScope Hearing Technologies Inc. He grew up in the hearing health industry, working alongside his grandfather through internships and mentorships. At the age of 10 years old, he became Chief Marketing Officer and Chief Operating Officer of his parent’s private hearing aid practice, the largest in Northern California and the second largest in the state. Matthew has shown his leadership ability by creating distribution partnerships with big industry names and independent retailers/pharmacies.

Kim Moore is the Chief Financial Officer of InnerScope Hearing Technologies Inc. She has worked in the hearing aid industry for over 45 years, helping her father maintain his hearing aid practice in Central Valley, California. She began working on marketing with her father at the age of eight, learning that no customer walks through the door without proper advertising and marketing. As a licensed hearing instrument specialist, Kim has given hearing tests to more than 30,000 people.

Mark Moore is the Chairman and Co-Founder of InnerScope Hearing Technologies Inc. He has over 35 years of experience in hearing aid dispensing, practice management, private label brand management and hearing aid marketing. He has personally fit hearing aids to over 10,000 hearing-impaired people. In addition, he has been responsible for developing and testing proven new industry marketing and advertising methods and best practice strategies, which has made him one of the most sought-after experts in the hearing aid industry. Mark was previously a columnist for Advanced for Audiologists, a global industry publication, and served on the American Academy of Audiology (AAA) advisory board for AudiologyNow conventions. He has also developed patented and patent-pending nutritional supplements for hearing-related issues, aural rehabilitation programs and low-level laser therapy for tinnitus and sensorineural hearing loss.

InnerScope Hearing Technologies Inc. (INND), closed Monday's trading session at $0.0084, off by 2.3256%, on 25,090,690 volume with 425 trades. The average volume for the last 3 months is 25.091M and the stock's 52-week low/high is $0.000001/$0.098.

Recent News

• InnerScope Hearing Technologies Inc. (OTC: INND) - InnerScope Hearing Technologies Inc. (INND) Set to Revolutionize the US Hearing Aid Market
• InnerScope Hearing Technologies Inc. (INND) Showcases Unmatched Hearing Technology During Home Health and Diabetes Care Program
• InvestorNewsBreaks - InnerScope Hearing Technologies Inc. (INND) Announces Participation in Home Health & Diabetes Care Program